As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...

Novo Nordisk, the Denmark-based pharmaceutical company that makes Ozempic and Wegovy, looks like it's being toppled off its ...

Danish drugmaker Novo Nordisk (NVO) has implemented a hiring freeze, which will apply across all markets and departments, ...

Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard ...

Novo Nordisk is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for ...

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of reallocating resources to the company’s “main core” of metabolic disease.

U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Lars Fruergaard Jorgensen So, Sachin in terms of, increased SG&A and also looking into 2020, I cannot get into details on that we do the full year guidance when we release the annual accounts.

Lars Fruergaard Jørgensen says: “Serving as Novo Nordisk’s CEO for the past eight years has been a privilege and an experience that I will always cherish.